Courtesy of Benzinga.
Transcept Pharmaceuticals (Nasdaq: TSPT) today announced the dismissal of the derivative lawsuit by the Court of Chancery of the State of Delaware. The derivative lawsuit was filed on October 24, 2013, by a shareholder, Retrophin Inc., against the Transcept Board of Directors, purporting to assert claims on behalf of Transcept, alleging that our Board of Directors approved and paid excessive compensation to our directors.